Tercica Inc. (TRCA)

[surf1944]

Tercica Reports Second Quarter 2008 Financial Results
Thursday July 31, 1:30 am ET

BRISBANE, Calif.--(BUSINESS WIRE)--Tercica, Inc. (Nasdaq: TRCA - News) today announced financial results for the quarter ended June 30, 2008. Net product sales totaled $6.2 million, compared to $2.0 million in the second quarter of 2007. Net product sales for Increlex® and Somatuline® Depot in the second quarter of 2008 were $4.6 million and $1.6 million, respectively.
Net loss for the second quarter of 2008 was $11.4 million, or $0.22 per share, compared to a net loss of $12.8 million, or $0.26 per share, for the second quarter of 2007.

Cash, cash equivalents and short-term investments as of June 30, 2008 were $71.4 million, compared to $94.9 million as of March 31, 2008.

Company Updates

Agreement and Plan of Merger with Ipsen.


On June 4, 2008, Tercica announced that Tercica and an affiliate of Ipsen, S.A. entered into an agreement and plan of merger by which an affiliate of Ipsen would acquire all of the shares of Tercica common stock that Ipsen does not currently own at a price of $9.00 per share in cash.
On July 24, 2008, Tercica announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and clearance by the German antitrust regulatory authority in connection with the agreement and plan of merger. Assuming satisfaction of the closing conditions in the agreement and plan of merger, including stockholder approval, Tercica estimates that the completion of the merger transaction should take effect late in the third quarter or early in the fourth quarter of 2008.
On July 24, 2008, Tercica also announced that Ipsen exercised in full the warrant issued by Tercica in October 2006, converted in full three convertible notes issued by Tercica in October 2006 and September 2007, and purchased 410,831 additional shares of the common stock of Tercica upon exercise of its pro rata rights to purchase shares in connection with other equity issuances by Tercica. Total cash proceeds from the warrant exercise and purchase of additional shares by Ipsen were $40.3 million.
http://biz.yahoo.com/bw/080731/20080730006479.html?.v=1

[read_this_n0w]

TRCA main platform was free igf1 and optin rights for iplex (igf1 ifgbp3 compound)

No, a lot more to the INSM/TRCA story. Feel free to comment if anything unclear

Insm lost a production patent case against trca/dna (with trca being the licensee from dna) on the a part of the production process of IGF1.
(no such patent in europe due to retractment on prior art btw)

Jury found in trca/dna's favour.
Result was not a verdict though, but a settlement.

insm was allowed to continue expanded acces program in italy where iplex is used in ALS patients. Patients use court orders to get mandatory reimbursement from italian ministry of health. Reimbursement 140.000 euros per patient per year.
Latest update in march were 90 expanded access ALS patients , up from 30 in sept '07.
There is no fixed denial or approval for futher ALS development. Cephalon holds patent right of use for igf1 in ALS, but the eap has the full cooperation of cephalon.

INSM was forced to withdraw iplex from the short stature market for which it is approved and not sell it for that indicatin in the US.

INSM was allowed to pursue MMD, ROP, HARS as specifically permitted indications for the igf1-igfbp3 compound.
(which can be given in up to four time higher dosage than free igf1, not to mention anti carcigenic properties of bp3 compound on its own)

The catch is that trca has a first optin right on orphan indications and genentech on non orphan indications for the specifically allowed indications.

Deal of the optin: Upon IIb data trca and/or genentech has the right to optin within 90 days. Optin consists of reimbursement of 50% of all past cost and 50% of all future cost in return for 50% of the profit, where insm remains in control of production/pricing.
If no optin is used than insm only has to pay a 4% royalty.

results for MMD expected early 2009.

So the iplex program is still very much alive.

Since iplex is a complex biologic as well and insm owns its own (now fda approved) production facility, in 2007 they started increasing their focus on biognerics.

They have been granted and started a phase I study for ins-19 (neupogen generic) several weeks ago in europe.
They intend to use that data in any US phase III trial that the company expects will be included in US biogeneric legislation.

The company is looking for a biogenric partner since they cannot finance phase III biogeneric trials on their own, nor dot hey have the marketing clout to push it on the market.
They need one prior to end of Q3 as well due to cash restraints. (might be longer if ALS patient count keeps rising)


IPlex (igf1-igfbp3) indications:

Myotonic muscular dystrophy still very much on the table, 2mln grant for phase IIb and a very enthusiastic dr moxley who tried free igf1 in the 90s but abandoned it due to dosage restraints.

ROP (Retinopathy of prematurity)=further out, being researched externally, no big funds from insm

HARS (hiv lipodystrophy)= on backburner atm to conserve cash

NDGA,( cancer drug ): other insm compound has been started in a phase II trial payed and done by UCSF (university of san francisco) in prostate cancer indication.

BP3 binding protein itself has anti carcigenic properties of its own and has proven to increase efficacy in herceptin amonst others.
Do not see insm pursuign that one on their own on the short term due to trial sizes and cash burn.
More likely to see a partner for that part.

Their short term focus besides iplex is very much biognerics though which they have proven to be very skilled in producing.
Trca has/had alot of trouble just getting free igf1 produced by contract production.
Insm does its own production with no batch failures.

INMS general DD
http://investorshub.advfn.com/boards/board.aspx?board_id=1433

recent phase II prostate cancer trial run by UCSF
http://www.clinicaltrials.gov/ct2/show/NCT00678015?term=ndga&rank=1

Biogenerics Overview
http://www.xs4all.nl/~surg3on/INSM/20080429-Insmed_CBI_Conference.pdf

[foodcourt1]

Wow, sometimes gambling in the pinks does pay off !

[surf1944]

Dropping MOD position, with the TRCA symbol buyout stock will be gone soon.

surf

[foodcourt1]

I bought a couple of hundred shares yesterday, probably go down today which would be typical for me.

[Aiming4]

Wow... congrats to anyone holding TRCA.

I'm not since I didn't like them as a company... oops!

[surf1944]

Ipsen to Acquire Tercica
Wednesday June 4, 9:00 pm ET
-- $9.00 per Share to Be Paid in Cash --

BRISBANE, Calif.--(BUSINESS WIRE)--Tercica, Inc. (Nasdaq: TRCA - News) today announced that Tercica and Ipsen, S.A. (Euronext: IPN) have entered into a definitive merger agreement by which an affiliate of Ipsen would acquire all of the shares of Tercica common stock that Ipsen does not currently own at a price of $9.00 per share in cash, which values Tercica at approximately $663 million. This transaction, which is subject to approval by Tercica stockholders holding a majority of the outstanding Tercica common stock, has been unanimously approved by Tercica’s Board of Directors following recommendation and approval by a Special Committee of Tercica’s Board of Directors comprised of three independent non-employee directors.

“The combination of Ipsen’s and Tercica’s development and product portfolios provides the opportunity to create a leading global endocrinology company,” said John A. Scarlett, M.D., Chief Executive Officer of Tercica. “We believe this transaction recognizes the value we have created at Tercica and provides our stockholders with attractive financial terms.”

Ipsen and its affiliates currently own approximately 25.3% of the outstanding Tercica common stock. Ipsen has agreed to exercise its outstanding Tercica warrant and convert its outstanding Tercica convertible notes promptly following today’s agreement. Upon such exercise and conversion, Ipsen and its affiliates will own approximately 42.7% of the outstanding Tercica common stock.

Certain stockholders of Tercica, who collectively own 1.4% of the outstanding Tercica common stock (after giving effect to the exercise and conversion of the warrants and convertible notes held by Ipsen and its affiliates), have executed voting agreements in conjunction with the merger pursuant to which they have agreed to vote the shares of Tercica common stock they hold in favor of the transaction. Ipsen and its affiliates have also agreed to vote their Tercica shares in favor of the merger.

Ipsen intends to finance this transaction through a combination of existing internal financial resources and bank loan financing.

The proposed cash offer represents a 104% premium to Tercica’s closing price on June 4, 2008 and a 74% premium to the volume-weighted average closing share price during the last three months.

Tercica’s Board of Directors, following the unanimous recommendation and approval by the Special Committee of Tercica’s Board of Directors who were advised by independent legal and financial advisors, have approved the merger agreement and recommend that Tercica’s stockholders vote to approve the merger.

The completion of the merger is subject to the satisfaction or waiver of customary closing conditions, including expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

Lehman Brothers is serving as financial advisor, and Morris, Nichols, Arsht & Tunnell LLP is serving as legal counsel, to the Special Committee of the Board of Directors of Tercica, and Tercica is represented by Cooley Godward Kronish LLP, Palo Alto, California.

[dalcindo]

TRCA - Look whether UTC-2 gets confirmation:

For now, DTC-2 is in control:


Hope this helps.

D.

In response to:
Posted by: read_this_n0w
In reply to: dalcindo who wrote msg# 255 Date:5/18/2008 3:50:33 PM
Post #of 257

I keep appreciating your feedbacks.
Could you take a peek at TRCA? Do not intend to invest in it, but would like to get some clues on its chart.

Downtrend, what would you see as support levels?
and what would you make of mid/longterm trend with what channels possibly?
And will you look at stoch or rsi mostly there combined with macd?

Its a kind of competitor of my pet stock, revenue lacked last week quarterly CC and cash burn stayed high. Still solid 4 quarters of cash in the bank.

[surf1944]

Tercica nears 2-year low on larger 1Q loss
Tuesday May 13, 2:15 pm ET
Tercica stock slides after 1st-quarter loss surpasses estimates and revenue falls short

NEW YORK (AP) -- Shares of Tercica Inc. fell to their lowest price in almost two years Tuesday after the biopharmaceutical company posted disappointing first-quarter results, including weak sales of key drugs and higher expenses.

Tercica's loss swelled 41 percent for the period to $17.5 million, or 34 cents per share, from $12.4 million, or 25 cents per share a year ago. Revenue more than tripled to $4.6 million from $1.3 million.

According to Thomson Financial, analysts expected a loss of 30 cents per share, on average, and $5.9 million in revenue for the Brisbane, Calif., company.

Sales of Tercica's growth hormone deficiency treatment Increlex rose to $3.4 million, from $1.1 million a year ago. The company posted $1 million in revenue from sales of Somatuline Depot, a treatment for acromegaly, a hormone disorder that can make the feet, hands, nose and mouth grow to unusually large sizes.

However, costs grew 58 percent due to larger sales and manufacturing costs, along with greater administrative expenses.

In Tuesday afternoon trading, shares fell 95 cents, or 19 percent, to $4.04 -- their lowest price since June 2006.

Baird analyst Christopher Raymond said Increlex revenue fell slightly from $3.6 million in the fourth quarter. He cut his revenue estimates and predicted larger losses, reducing his price target to $6 per share from $7.

However, Lehman Brothers analyst Jim Birchenough said he was encouraged that Tercica maintained its revenue outlook of $30 million to $37 million. He said the approval of Increlex in the European Union and Somatuline's launch in the U.S. will boost the company's results in the fourth quarter.

[surf1944]

Tercica Reports First Quarter 2008 Financial Results
Monday May 12, 4:05 pm ET

BRISBANE, Calif.--(BUSINESS WIRE)--Tercica, Inc. (Nasdaq:TRCA - News) today announced financial results for the quarter ended March 31, 2008. Total net product sales totaled $4.3 million, compared to $1.1 million in the first quarter of 2007. Net product sales for Increlex® and Somatuline® Depot in the first quarter 2008 were $3.4 million and $1.0 million, respectively.

Net loss for the quarter was $17.5 million, or $0.34 per share, compared to a net loss of $12.4 million, or $0.25 per share, for the first quarter of 2007.

Research and development expenses for the first quarter of 2008 were $6.1 million, compared to $4.9 million for the first quarter of 2007, due to increases in development activities associated with Tercica’s next-generation growth hormone product candidates. Selling, general and administrative expenses for the first quarter of 2008 were $12.4 million, compared to $9.6 million for the first quarter of 2007, due to increases in sales and marketing costs associated with the launch of Somatuline® Depot.

Cash, cash equivalents and short-term investments as of March 31, 2008 were $94.9 million, compared to $113.5 million as of December 31, 2007.

“The launch of Somatuline Depot is progressing well. Sales of Increlex in the first quarter reflected seasonality in the short stature market, reductions in inventory levels at certain key specialty pharmacies, as well as delays in commercial shipments to patients who have switched their insurers. With year to date revenues as of today totaling approximately $7.4 million, we remain on track to achieve our 2008 total revenue guidance of $30 to $37 million and year-end cash guidance of $40 million,” said John A. Scarlett, M.D., Tercica’s Chief Executive Officer. “Also regarding Increlex, initial efficacy and safety data from our IGFD Registry was well received when presented to participating investigators in February 2008. This is the first Increlex data pertaining to children who are representative of the patient population being treated by physicians today. We are pleased with the growth rates seen on Increlex therapy and with the positive safety data that were presented,” he added.

Product Updates:
http://biz.yahoo.com/bw/080512/20080512006317.html?.v=1

[surf1944]

Form 8-K for TERCICA INC
28-Mar-2008
Change in Directors or Principal Officers

http://biz.yahoo.com/e/080328/trca8-k.html

[surf1944]

Tercica Initiates Phase II Clinical Trial with Next-Generation Growth Hormone Product for the Treatment of Short Stature
Tuesday January 22, 4:05 pm ET

BRISBANE, Calif.--(BUSINESS WIRE)--Tercica, Inc. (NASDAQ: TRCA - News) today announced that the Company has begun dosing the first patient in a Phase II clinical study evaluating the combination of Genentech, Inc.’s recombinant human growth hormone Nutropin AQ® (somatropin [rDNA origin]) and Tercica’s recombinant insulin-like growth factor-1 Increlex® (mecasermin [rDNA origin] injection). The primary objective of this trial is to assess the efficacy, measured as first-year height velocity, and safety of three different combination regimens of growth hormone and IGF-1 compared to growth hormone alone in the treatment of short stature associated with IGF-1 deficiency.

“With demonstrated synergies in pre-clinical studies, the combination of growth hormone and IGF-1 could have the potential for several important therapeutic benefits compared to either growth hormone or IGF-1 monotherapy alone for the treatment of patients with short stature,” said John A. Scarlett, M.D., Tercica’s President and Chief Executive Officer. “We are pleased to be starting the Phase II clinical trial just six months after signing the agreement with Genentech,” continued Dr. Scarlett.

Development of GH/IGF-1 Combination Product in Short Stature

Potential of GH/IGF-1 Combination Product: The combination product will be studied in children with short stature not associated with growth hormone deficiency, who also have low IGF-1 levels. A potential cause of short stature in this group of patients could be a suboptimal IGF-1 secretion in response to growth hormone stimulation alone. Pre-clinical studies suggest that co-administration of GH and IGF-1 may increase specific growth responses greater than growth hormone alone. Therefore, Tercica believes that treatment with a combination of both GH and IGF-1 may be superior to monotherapy of growth hormone alone in a subpopulation of children with low IGF-1 and short stature not associated with growth hormone deficiency.

Study design: This Phase II study, referred to as MS316, is a randomized clinical trial comparing three different combination regimens to growth hormone alone. The three combination arms each contain a different ratio of IGF-1 to growth hormone. The primary efficacy endpoint is height velocity during the first 12 months of therapy. After evaluation of the primary endpoint, the study will be continued to evaluate long-term effects. Approximately 100 patients will be enrolled in the study. Tercica expects to complete enrollment in mid-2009.

[surf1944]

Bullish MACD Crossovers (TRCA)

[was WALL STREET KID]

Over 50% of the float is short now:


TRCA $ 6.86
Tercica Inc. 0.04
Shares Short 3,275,600
Days to Cover (Short Ratio) 33.0
Short % of Float 56.57 %
Shares Short - Prior 3,375,200
Short % Increase / Decrease -2.95 %
Squeeze RankingTM 653
% from 52-Wk HIGH ( 7.89 ) -15.01 %
% from 52-Wk LOW ( 4.45 ) 35.13 %
% from 200-Day MA ( 6.08 ) 11.37 %
% from 50-Day MA ( 6.24 )
9.04 %
Price % Change (52-Wk) 35.00 %
Trading Volume - Today 19,219
Trading Volume - Average 99,200
Trading Volume Vs. Avg. 19.37 %
Total Shares - Float 5,790,000
Total Shares - Outstanding 51,447,870
% Held by Insiders 33.94 %
% Held by Institutions 35.70 %
Market Cap 352,932,388
EPS -1.39

[surf1944]

Tercica Reports Third Quarter 2007 Financial Results

--Somatuline Depot Launched in the U.S. for the Treatment of Acromegaly--

--Increlex Has Now Been Prescribed for More Than 1,000 Patients--

Tercica, Inc. (Nasdaq:TRCA) today announced financial results for the quarter ended September 30, 2007. Net product sales totaled $2.9 million, compared with $316,000 in the third quarter of 2006. Total net revenues for the quarter totaled $23.4 million, including a licensing milestone of $20.3 million in connection with the marketing authorization of Increlex® 10 mg/ml solution for injection in the European Union pursuant to the Increlex® License Agreement with Ipsen. Net profit for the quarter was $3.4 million, or $0.07 per share, compared with a net loss of $13.1 million, or $0.35 per share, for the third quarter of 2006. Total costs and expenses were $19.1 million for the quarter ended September 30, 2007, compared with $14.2 million for the same period in 2006.

Tercica reported product sales of $6.0 million for the nine months ended September 30, 2007. Total net revenues for the nine months ended September 30, 2007, including the licensing milestone of $20.3 million, were $26.9 million. Net loss for the first nine months of 2007 was $21.8 million, or $0.43 per share, compared with $42.0 million, or $1.14 per share, for the first nine months of 2006. Total costs and expenses for the nine months ended September 30, 2007 were $50.4 million, compared with $45.1 million for the same period in 2006.

Cash, cash equivalents and short-term investments as of September 30, 2007 were $127.7 million, compared with $98.0 million as of June 30, 2007.

“Along with continued positive commercial momentum for Increlex, we achieved two major corporate milestones in the third quarter when Somatuline Depot was approved in the United States for the treatment of acromegaly and Increlex was granted marketing authorization in the European Union for severe Primary IGFD,” said John A. Scarlett, M.D., Tercica’s President and Chief Executive Officer. “With our launch of Somatuline Depot, Tercica has now become a well-balanced biotechnology company with two commercial products and an exciting pipeline that includes our next-generation growth hormone products targeting an existing billion dollar market opportunity,” added Dr. Scarlett.

Recent Highlights and Updates

Increlex®

* On August 3, 2007, the European Commission granted marketing authorization for Increlex®. The authorized indication is for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor-1 deficiency.
* The European Medicines Agency (EMEA) has granted Increlex® orphan drug exclusivity for the treatment of severe Primary IGFD, providing a 10-year period of marketing exclusivity for the approved indication.
* Increlex® net product sales increased 39% to $2.9 million in the third quarter of 2007, compared with $2.0 million in the second quarter of 2007.
* A major commercial milestone was achieved when Increlex® was prescribed for the 1,000th patient with short stature.
* As of September 30, 2007, a cumulative total of over 600 patients had received reimbursement approval.
* As of September 30, 2007, 307 physicians, or more than 60% of the pediatric endocrinologists to whom we promote, had prescribed Increlex®.

Somatuline® Depot

* On August 30, 2007, Tercica received notice of approval from the U.S. Food and Drug Administration (FDA) for marketing Somatuline® Depot (lanreotide) Injection 60, 90 and 120 mg/ml in the United States for the treatment of acromegaly.
* The FDA has granted Somatuline® Depot orphan drug exclusivity for the treatment of acromegaly, providing a seven-year period of marketing exclusivity.
* In the third quarter, the company completed the planned expansion of its sales force to launch Somatuline® Depot which will soon be available for commercial use in the United States.
* Enrollment began in the SALSA study, which is an open-label clinical study of Somatuline® Depot designed to assess self or partner administration in American patients with acromegaly. A similar study was conducted previously in the United Kingdom.

Financial

* In connection with Tercica’s Increlex® license with Ipsen, the marketing authorization of Increlex® in the European Union triggered a €15 million (approximately $19.3 million, net of withholding taxes) milestone payment by Ipsen to Tercica. Pursuant to our Somatuline® Depot license with Ipsen, the FDA approval of Somatuline® Depot triggered issuance of two notes by Tercica to Ipsen. The first note is a €30 million note (convertible into Tercica common stock at a conversion price of €5.92). The second note is a $15 million note (convertible into Tercica common stock at $7.41). The €30 million note was issued to Ipsen in lieu of the milestone payment of €30 million from Tercica to Ipsen that was triggered by the FDA approval of Somatuline® Depot. The $15 million note was issued to Ipsen for cash.
* In connection with the Genentech Combination Product Development and Commercialization Agreement entered into in July 2007 and a stock purchase by Ipsen, Tercica received cash proceeds of $6.9 million from share issuance to Genentech and Ipsen in the third quarter.
* With the receipt of the cash proceeds associated with the sale of equity and the $15 million convertible note, Tercica finished the quarter with $127.7 million in cash. Tercica now expects to end 2007 with approximately $110 million in cash.
* Tercica affirmed its expectation that 2007 Increlex® revenues will total approximately $9-10 million.

Conference Call and Webcast Information

Tercica’s senior management team will review third quarter financial results via a conference call and webcast today beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To access the live teleconference, please dial 888-803-8296 (U.S.) or 706-634-1250 (international), and reference the conference ID# 20286721. To access the webcast, please go to the Events page on the Investors section of the Company’s Web site at www.tercica.com.

A telephone replay will be available approximately two hours after the call for 48 hours by dialing [phone] from the U.S., or [phone] for international callers, and entering reservation number 20286721. A replay of the webcast will be available on the Company’s Web site for 21 days at www.tercica.com.

About Tercica

Tercica is a biopharmaceutical company committed to improving endocrine health by partnering with the endocrine community to develop and commercialize new therapeutics for pediatric and adult growth disorders, and for adult metabolic disorders. For further information on Tercica, please visit www.tercica.com.

Safe Harbor Statement

Except for the historical statements contained herein, this press release contains forward-looking statements concerning the Company's prospects and expectations, including without limitation, that the Company expects to end 2007 with approximately $110 million in cash, that 2007 Increlex® revenues will be $9-10 million, and that Somatuline® Depot will soon be available for commercial use in the United States. Because Tercica's forward-looking statements are subject to risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, risks and uncertainties related to the following: (i) there may be significant unexpected expenditures; and (ii) sales of Increlex® may be less than expected due to physician discretion or adverse events; and (iii) the FDA may hold the first shipments of Somatuline® Depot pending their inspection; and (iv) the risks and uncertainties disclosed from time- to-time in reports filed by Tercica, including most recently Tercica's Form 10-Q for the quarter ending June 30, 2007 filed with the SEC on August 2, 2007. Tercica disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.

TERCICA, INC.
(In thousands, except per share data)
(Unaudited)

Statements of Operations

Three Months Ended September 30,


Nine Months Ended September 30,


2007 2006 2007 2006

Net revenues
Net product sales $ 2,851 $ 316 $ 5,990 $ 567
License revenue 20,537 — 20,925 —

Total net revenues 23,388 316 26,915 567

Costs and expenses:
Cost of sales 2,096 516 4,248 1,156

Research and development(a)
5,588 3,513 14,601 12,739

Selling, general and administrative(a)
11,409 10,162 31,562 31,252
Total costs and expenses 19,093 14,191 50,411 45,147

Income (loss) from operations 4,295 (13,875 ) (23,496 ) (44,580 )

Interest expense 334 — 712 —
Interest and other income, net 1,429 812 4,397 2,564
Other expense 951 — 951 —

Income (loss) before income taxes 4,439 (13,063 ) (20,762 ) (42,016 )
Provision for income taxes 1,017 — 1,017 —

Net income (loss) $ 3,422 $ (13,063 ) $ (21,779 ) $ (42,016 )


Basic net gain (loss) per share $ 0.07 $ (0.35 ) $ (0.43 ) $ (1.14 )
Shares used to compute basic net gain (loss) per share 51,041 37,550 50,458 36,906

Diluted net gain (loss) per share $ 0.07 $ (0.35 ) $ (0.43 ) $ (1.14 )
Shares used to compute diluted net gain (loss) per share 51,345 37,550 50,458 36,906



(a) Includes non-cash stock-based compensation expense as follows:

Research and development $ 405 $ 525 $ 1,454 $ 1,502
Selling, general and administrative 1,086 1,027 3,173 2,814
Total $ 1,491 $ 1,552 $ 4,627 $ 4,316
September 30, December 31,
2007 2006

Balance Sheet Data
Cash, cash equivalents and short-term investments $ 127,749 $ 125,575
Restricted short-term investments 340 340
Total assets 189,072 137,687

Total liabilities
108,918 47,756
Total stockholders’ equity 80,154 89,931

Investor and Media Contact:
Tercica, Inc.
Fredrik Wiklund
Senior Director, Investor Relations &
Corporate Development
650-624-4992
[e-mail]


Source: Business Wire (November 1, 2007 - 4:19 PM EDT)

News by QuoteMedia
www.quotemedia.com

[surf1944]

Stocks in a New Uptrend (Aroon) (TRCA)

CCI Buy Signals (TRCA)

[surf1944]

Bullish MACD Crossovers (TRCA)

[surf1944]

Parabolic SAR Buy Signals (TRCA)

[surf1944]

I would be a seller of TRCA on todays spike. The approval today triggers milestone payments to the company that TRCA acquired the drug rights from. The price is already built into the stock for this approval.

[surf1944]

Somatuline(R) Depot Receives FDA Marketing Approval for the Treatment of Acromegaly

Tercica Management Will Hold a Conference Call on August 31st at 9:00 a.m. EDT/ 6:00 a.m. PDT

Tercica, Inc. (NASDAQ:TRCA) today announced that its partner Ipsen (Euronext:IPN) has received notice of approval from the U.S. Food and Drug Administration (FDA) for marketing Somatuline® Depot (lanreotide) injection 60, 90 and 120 mg/ml in the United States.

Somatuline® Depot is indicated for the long-term treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. Somatuline® Depot will be available in a pre-filled syringe eliminating any need for reconstitution and thus enabling freedom of easy administration to patients. The FDA has also designated Somatuline® Depot as an orphan drug for acromegaly. The Orphan Drug Act provides a seven-year period of exclusive marketing to the first manufacturer who obtains marketing approval for a designated orphan product.

In October 2006, Ipsen granted to Tercica the development and commercialization rights for Somatuline® Depot in the United States and Canada. At the same time, Ipsen acquired a 25% stake in Tercica on a non-diluted basis. According to the terms of the agreement, the FDA approval of Somatuline® Depot triggers a €30 million (approximately $41 million) milestone payment that Tercica will pay to Ipsen by issuing a convertible bond (converted into Tercica common stock at a conversion price of €5.92). Tercica will simultaneously issue an additional $15 million convertible bond to Ipsen (converted into Tercica common stock at a conversion price of $7.41), which will be paid in cash to Tercica.

“We are delighted with the approval of Somatuline Depot. Somatuline Depot is the only long-acting acromegaly therapy available in a pre-filled syringe, and the only long-acting somatostatin analogue that does not require reconstitution prior to injection. Somatuline Depot provides a significant medical advance for the treatment of acromegaly by offering physicians, nurses, and patients the freedom of easy injections and ready-to-go simplicity. We expect to launch Somatuline Depot in the U.S. in approximately eight weeks,” said John A. Scarlett, M.D., Tercica’s President and Chief Executive Officer. “The approval of Somatuline Depot represents a major step in our goal of establishing Tercica as the leading U.S. endocrine and metabolic company. This will be the second market introduction of an important endocrine product made by Tercica within a two-year period. Tercica has now become a well balanced biotechnology company with two commercial products and an exciting pipeline that includes our next generation growth hormone products targeting existing billion dollar market opportunities,” added Dr. Scarlett.

About Acromegaly

Acromegaly is a disorder caused by the over-production of growth hormone usually by a benign tumor of the anterior pituitary gland. Acromegaly occurs in approximately 60 people per million of population. In acromegaly patients, the pituitary gland releases too much growth hormone into the bloodstream, the growth hormone then triggers the liver to produce IGF-1, which in turn directly stimulates bone and tissue growth. The most common signs and symptoms of this serious condition include: enlarged hands, feet, and head; facial changes such as bulging forehead, enlarged lower jaw, tongue and lips; wider spacing between teeth; enlarged heart, liver, kidneys, spleen and other organs; joint pain and fatigue; reduced sex drive; and loss of concentration.

About the Marketing Approval

This decision follows the filing by Ipsen of a New Drug Application (NDA) for Somatuline® Depot in the United States in December 2006. The effect of Somatuline® Depot on reducing growth hormone and IGF-levels and control of symptoms in patients with acromegaly was studied in two long-term, multiple-dose, randomized multicenter studies performed in the United States and in Europe. Somatuline® Depot demonstrated its ability to decrease the levels of growth hormone and IGF-1 in the majority of patients over a one-year period.

About Somatuline® Depot

Somatuline® Depot (also marketed as Somatuline® Autogel® outside the United States) is a sustained-release formulation for injection containing lanreotide, a somatostatin analogue (a hormone that inhibits the release of growth hormone). Somatuline® Depot was initially developed and continues to be used mainly in the treatment of acromegaly, a disorder caused by the over-production of growth hormone or prolactin due to a benign tumor of the anterior pituitary gland. This product subsequently underwent further development in Europe in the treatment of symptoms associated with neuroendocrine tumors (particularly of a carcinoid type). Ipsen believes that the Somatuline® Depot formulation, to which it holds the patent, represents a major technological advance. As far as Ipsen is aware, this represents the first semi-solid formulation for injection without any excipient, since the active substance itself controls the sustained release. Somatuline® Depot releases the active substance with no excipient other than water over a period of at least 28 days, thus requiring just one injection per month, compared with the two or three injections previously necessary. This product is presented in a pre-filled syringe for easier administration.

Active Substance

The active substance in Somatuline® Depot is lanreotide, which inhibits the growth and secretion of several endocrine, exocrine and paracrine functions. It is particularly effective in inhibiting the secretion of growth hormone.

Indications

Somatuline® Depot is indicated for the treatment of acromegaly when circulating levels of growth hormone remain high despite surgery or radiotherapy. Somatuline® inhibits growth hormone release and thus controls the therapeutic and relieves the symptoms associated with elevated levels of this hormone.

[surf1944]

Stocks in a New Uptrend (Aroon) (TRCA)

[surf1944]

Stocks in a New Uptrend (ADX) (TRCA)

[surf1944]

CCI Buy Signals (TRCA) from nightly stockcharts.com scan

[surf1944]

Tercica Announces Agreement with Genentech for Worldwide Growth Hormone and IGF-1 Combination Product Development and Commercialization

Combination Products for the Potential Treatment of Short Stature and Adult Growth Hormone Deficiency

Tercica May Receive up to $53 Million in Equity Payments, Opt-in Payments, R&D Reimbursement and Milestone Payments from Genentech

Pending FDA guidance, Tercica intends to initiate Phase II Clinical Trials in 2008

Tercica, Inc. (Nasdaq:TRCA) today announced an agreement with Genentech, Inc. for the development, manufacture and worldwide commercialization of two products containing Genentech’s recombinant human growth hormone Nutropin AQ® [somatropin (rDNA origin)] and Tercica’s recombinant insulin-like growth factor-1 Increlex® (mecasermin [rDNA origin] injection) for the treatment of short stature, adult growth hormone deficiency (AGHD), and potentially other metabolic disorders. Nutropin AQ® and Increlex® were originally designed and formulated so that the therapies could be combined and potentially given as a single, daily injection.

Pending U.S. Food and Drug Administration guidance and timely IND acceptance, Tercica plans to initiate Phase II clinical development in 2008 of one combination product for patients with low IGF-1 levels and short stature not associated with growth hormone deficiency; and a second combination product for patients with AGHD.

“This collaboration allows us to embark on two new and exciting development programs that each have scientific merit,” said John A. Scarlett, M.D., Tercica’s President and Chief Executive Officer. “With demonstrated synergies in pre-clinical studies, the combination of rhGH and rhIGF-1 could have the potential for several important therapeutic benefits compared to either rhGH or rhIGF-1 monotherapy alone for the treatment of patients with short stature and AGHD and potentially other adult metabolic disorders. With our current cash position, equity sales associated with this agreement and possible collaboration for both programs through sublicensing of Tercica’s ex-U.S. rights, Tercica continues to have profitability in 2010 as a goal without additional equity financing unless needed to support additional new initiatives or strategic opportunities.”

Terms of Agreement

Under the terms of the collaboration, Tercica may be eligible to receive a total of up to $53 million in equity payments, opt-in payments, research and development cost reimbursement, and milestone payments. In connection with the transaction, Genentech will purchase 708,591 shares of Tercica’s common stock for $4 million.

Tercica will fund and lead initial development efforts for both combination products. Genentech has certain rights to opt-in to the development programs for both products. The opt-in rights remain open until completion of a Phase II clinical study for each product that is sufficient to enable a pivotal trial.

Upon exercise of any opt-in by Genentech, Genentech shall reimburse certain incurred research and development costs. Following such exercise by Genentech, a cost and profit share structure will take effect for all future development and commercial activities of both combination products, and Genentech will have certain commercialization rights, including the right to co-promote both combination products upon regulatory approval. If Genentech does not exercise any of its opt-in rights, then Tercica will have full development and commercialization rights to the combination products, and will owe Genentech royalties on worldwide sales.

Development of GH/IGF-1 Combination Product

About Increlex®(mecasermin [rDNA origin] injection): The active ingredient of Increlex® is recombinant human insulin-like growth factor-1 (IGF-1). IGF-1 is the direct mediator of growth hormone's (GH) effect on statural growth, and must be present for normal growth of bones and cartilage in children. In Primary IGFD, children's serum IGF-1 levels are low, despite the presence of a normal or elevated GH level. Without adequate IGF-1, children cannot achieve normal height. In children with this disorder, low IGF-1 levels are due to growth hormone resistance associated with mutations in GH receptors, post-GH receptor signaling pathways, or to defects in IGF-1 gene expression. Increlex® has been marketed in the United States by Tercica since early 2006. Exclusive rights to develop and commercialize Increlex® were licensed to Ipsen in October 2006 for all regions of the world except the United States, Japan, Canada, Taiwan and certain countries of the Middle East and North Africa.

About Nutropin AQ® [somatropin (rDNA origin)]: Nutropin AQ® [somatropin (rDNA origin) injection] is produced using recombinant DNA technology and has the same amino acid sequence as human growth hormone produced naturally in the human body. It is marketed as Nutropin AQ® in Austria, Denmark, Finland, France, Germany, Ireland, the Netherlands, Norway, Sweden, Portugal, Spain and the United Kingdom. Other regulatory reviews are underway in Europe and worldwide, excluding North America and Japan.

Nutropin AQ® is supplied as 10 mg of sterile liquid somatropin per cartridge for exclusive use with the Nutropin AQ® Pen, a simple, convenient, easy-to-use device for subcutaneous injection. Nutropin AQ® is approved for the treatment of GHD in children and adults, for the long-term treatment of short stature in children with Turner syndrome, the treatment of growth failure in chronic renal insufficiency patients prior to transplantation and the long-term treatment of children with idiopathic (of unknown origin) short stature (ISS).

Potential of GH/IGF-1 Combination Product for Short Stature: One combination product will initially be studied in patients with low IGF-1 levels and short stature not associated with growth hormone deficiency, for example ISS. A potential cause of short stature in this group of patients could be a suboptimal IGF-1 secretion in response to growth hormone stimulation alone. Pre-clinical studies suggest that co-administration of GH and IGF-1 may increase specific growth responses greater than either therapy alone. Therefore, Tercica believes that treatment with a combination of both GH and IGF-1 may be superior to monotherapy of either component alone in a subpopulation of children with low IGF-1 and short stature not associated with growth hormone deficiency.

Potential of GH/IGF-1 Combination Product for AGHD: A second combination product will initially be studied in the AGHD population. These patients have abnormalities in body composition (e.g., increased body fat and reduced lean muscle mass). Preclinical studies have suggested that co-administration of GH and IGF-1 result in synergistic effects on these parameters. Tercica also believes that delivered together as a combination product, some of the negative effects of each individual component could potentially be mitigated by the positive effects of the other, especially their effects on glucose metabolism. Upon review of the clinical data in AGHD, Tercica and Genentech will evaluate the attractiveness of this combination product in treating other metabolic disorders.

Conference Call and Webcast Information

Tercica’s senior management team will host an investment community conference call tomorrow to discuss the collaboration with Genentech beginning at 9:00 a.m. EDT. To access the live teleconference, please dial [phone] (U.S.) or [phone] (international) and reference the conference ID# 6557103. To access the webcast, please go to the Events page on the Investors section of the Company’s Web site at www.tercica.com.

A telephone replay will be available approximately two hours after the call for 48 hours by dialing [phone] from the U.S., or [phone] for international callers and entering reservation number 6557103. A replay of the webcast will be available on the Company’s Web site for 21 days at www.tercica.com.

About Tercica

Tercica is a biopharmaceutical company committed to improving endocrine health by partnering with the endocrine community to develop and commercialize new therapeutics for short stature and other metabolic disorders. For further information on Tercica, please visit www.tercica.com.

Safe Harbor Statement

Except for the historical statements contained herein, this press release contains forward-looking statements concerning Tercica’s prospects and expectations, including without limitation, that Tercica: (A) may receive from Genentech up to $53 million in equity, opt-in and milestone payments and research and development cost reimbursement; (B) plans to initiate Phase II clinical development of the combination products in 2008 for both short stature and AGHD; (C) believes that treatment with a combination of both GH and IGF-1 may offer several important therapeutic benefits when compared with, and be superior to monotherapy in a subpopulation of children with low IGF-1 and short stature not associated with growth hormone deficiency, and for patients with AGHD; (D) believes that for patients with AGHD, delivered together as a combination product, some of the negative effects of each individual component could potentially be mitigated by the positive effects of the other, especially their effects on glucose metabolism; and (E) continues to have profitability as a goal in 2010 without the need for additional equity financing. Because Tercica's forward-looking statements are subject to risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, risks and uncertainties related to the following: (i) for (A) (C) (D) and (E) above, data from Tercica’s clinical trials of the combination products may not demonstrate sufficient efficacy or safety for either clinical development or commercial purposes or to enable Tercica to receive any financial remuneration, and Genentech may never opt-in; (ii) for (B) above, the FDA may have concerns or requirements that impede Tercica from beginning the Phase II clinical trials in 2008 or cause Tercica to stop all clinical development of the combination products; (iii) also for (E) above, Tercica’s internal projections for revenues and costs through 2010 may be incorrect or not actually achieved, Tercica may be unable to sublicense its ex-U.S. rights on financial terms that it projects, or at all, and Tercica may undertake new and costly initiatives or strategic opportunities; and (iv) for (A) – (E) above, the risks and uncertainties of drug development and others risks and uncertainties disclosed from time-to-time in reports filed by Tercica, including most recently Tercica's Form 10-Q for the quarter ending March 31, 2007 filed with the SEC on May 4, 2007. Tercica disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.

Tercica, Inc.
Fredrik Wiklund
Senior Director, Investor Relations &
Corporate Development
650-624-4992
[e-mail]

Source: Business Wire (July 10, 2007 - 4:05 PM EDT)

[coinstarz]

http://www.unterberg.com/research/news/061506TRCAInitiationWEB.pdf

[coinstarz]

C.E Unterberg initates TRCA with an Underperform and a $2-3 tgt saying they expect continued clarity into the progress of Increlex's launch, they remain cautious on its future prospects. They say their cautiousness stems from Tercica's inferior safety profile when compared to that of its main competitor, Insmed's IPLEX. The firm notes Increlex had a 68% incidence of adverse events in its pivotal clinical trial compared to 48% for IPLEX

http://www.briefing.com/Investor/Public/MarketAnalysis/Calendars/UpgradesDowngra desAlphaSort.htm

[coinstarz]

Tercica: Growing Small
(Start-Up: Windhover's Review of Emerging Medical Ventures, December 2004 page 13)


Armed with a powerful, in-licensed late-stage molecule from Genentech, two-and-a half-year-old Tercica is about a year away from entering the eminently reachable market for treating short-stature children, a potentially significant segment of a $750 million annual US market. But unlike many start-up in-licensers that seek niche indications for their lead programs, Tercica won’t be able to fly under the radar of the competition.
Tercica is a pure asset play. It fits easily into a VC’s portfolio of companies which are creating value rapidly by seeking a quicker route to commercialization with products that already have a history in the clinic, but which for various reasons larger companies want to unload.

But Tercica is unusual in that its licenser looms as a significant competitor, with its version of growth hormone. Indeed, the success of IGF-1 depends on changing the mindset of pediatric endocrinologists who’ve had 40 years of comfortable experience with growth hormone—the only currently approved drug for short stature—in hundreds of thousands of patients. And Tercica will have to do this armed only with data from a single Phase III trial conducted several years ago by Genentech. That requisite medical marketing effort partly explains why Genentech parted with the molecule: the work could impede Genentech’s own selling efforts in an already established franchise that is virtually a cash cow that the big biotech projects will continue to grow at double-digit rates in the US.

Even if Genentech had good reason to turn away from IGF-1, others have responded favorably to it. The late-stage nature of the opportunity, the benefits of having an established E. coli-based manufacturing process from Genentech for making the peptide at scale, and confidence in the management team are factors in Tercica’s favor. Earlier this year, investors in Tercica’s IPO paid almost 2.5 times private investors’ average share price to buy the stock—a significant step-up given today’s parsimonious IPO pricing window.

Until the anticipated product launch, Tercica must work to define the portion of the short stature market it believes will benefit from IGF-1. Its best chance in the face of competition from growth hormone may be to link diagnosis to both drugs, so that rather than trying to fly below the radar screen of the growth hormone makers, they make it a tandem flight.

[coinstarz]

TRCA down trendline is terrible. Short sellers take control with Lehman Bro. The stock is way overvalued since the company has only one drug without any pipeline. Next week CC would not do too much good to the stock. Upside risk is 8.65, dowside risk is 4.65.

Strong Sell

[coinstarz]

excerpts from Ross Cap on first call By: Ulose123
Date: 02/28/06 11:03 am

seems the call on TRCA by Ross is hitting their stock, not only price but look who sold today--big institution. these are excerpts from the analyst firm, can not post URL as it is subscription only. Ross is not public and is not a brokerage so they do not come up on typical newswires b/c it is illegal to re-post without license fees...they are very well respected in the investment community and they do not own either stock.

"We believe that once iPlex is established in the market there will be little or no demand for Increlex." "Tercica does not have the longer term fundementals or resources that would support a multiple product pipeline, as its competitor, Insmed, clearly does."

"Our polling shows top endos will not recommend Increlex due to ongoing studies of dosing effectiveness. This is also a clear signal that Increlex did not capitalize on its 'first mover' advantage, as indicated by management on TRCA's recent earnings conference call."

http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=1608000820&tid=trca&sid=...

[coinstarz]

Let's talk about short strategy on this stock. Please note we do not bash this company without merit. We short it because it is overvalued. We want to make money....that is all...

[coinstarz]

Tercica Reports Fourth Quarter Financial Results; Conference Call Begins at 4:30 p.m. Eastern Time Today
Business Wire - February 15, 2006 16:01

BRISBANE, Calif., Feb 15, 2006 (BUSINESS WIRE) -- Tercica, Inc. (Nasdaq:TRCA) today announced financial and operating results for the fourth quarter and year ended December 31, 2005.

Financial Results

The net loss for the fourth quarter was $14.4 million, or $0.46 per share based on 31.5 million weighted-average shares outstanding, compared with a net loss of $11.2 million, or $0.46 per share based on 24.1 million weighted-average shares outstanding, for the fourth quarter of 2004.

Research and development expenses for the fourth quarter decreased to $4.7 million from $7.6 million for the prior year fourth quarter, due primarily to reduced GMP manufacturing activities that were required to support our NDA filing in early 2005.

Selling, general and administrative expenses for the fourth quarter were $8.9 million, up from $3.8 million for the comparable prior-year period, reflecting higher intellectual property litigation expense and pre-launch commercial activities for Increlex(TM).

Other expense for the quarter of $1.3 million consisted primarily of the non-cash charge related to the value of the warrants issued in connection with the Committed Equity Financing Facility with Kingsbridge Capital, which was expensed in the fourth quarter of 2005.

For the year, Tercica reported a net loss of $47.4 million, or $1.55 per share based on 30.6 million weighted-average shares outstanding, compared with a net loss of $41.0 million, or $2.12 per share based on 19.3 million weighted-average shares outstanding, for 2004.

Cash, cash equivalents and short-term investments as of December 31, 2005 were $58.6 million, compared with $52.0 million as of December 31, 2004. Tercica raised $34.5 million in gross proceeds from a financing completed in January 2006, which is not reflected on the 2005 year-end balance sheet.

"Our commercial team is diligently focused on the U.S. launch of Increlex, the only drug approved by the FDA for the long-term treatment of growth failure in children with severe Primary IGF-1 deficiency. I am delighted to report that we are successfully implementing our launch strategy, and that we achieved all our commercial objectives during the fourth quarter including commercial staffing, patient advocacy and reimbursement. Importantly, we began shipping Increlex on January 3, 2006, right on plan," said John A. Scarlett, M.D., Tercica's President and Chief Executive Officer.

Highlights of the fourth quarter and recent developments include:

-- Completion of the manufacturing, distribution and commercial operations requirements necessary to launch Increlex (mecasermin (rDNA origin) injection) in the U.S. on January 3, 2006 for the treatment of children afflicted with severe Primary IGFD.

-- Completion of the build out of the commercial organization, which now includes 24 sales representatives, three regional business directors and three national account executives.

-- Implementation of the TerciCare reimbursement support team, which facilitates the information exchange between patients, healthcare providers and health insurance companies to help patients gain appropriate reimbursement coverage for Increlex.

-- Submission of a marketing application in December 2005 for the regulatory approval of Increlex in the European Union (EU), with an expected commercial launch in January 2007; Tercica estimates that the number of children with severe Primary IGFD in the EU is approximately equal to that in the U.S.

-- Completion of a public offering of common stock in January 2006, raising gross proceeds of $34.5 million.

2006 Financial Guidance

The Company also announced that it expects cash burn in 2006, including working capital requirements and excluding the impact of revenue and related product costs, to be in the range of $63 million to $69 million. Tercica will provide revenue guidance upon assessment of two quarters of product sales.

Conference Call and Webcast Information

Management will be hosting an investment community conference call today beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss fourth quarter financial results, provide a business update including a discussion of enrollment and conduct of the MS301 and MS308 clinical trials, and to answer questions. To participate by telephone, please dial [phone] from the U.S., or [phone] from outside the U.S.

A telephone replay of the conference call will be available for 48 hours beginning February 15 within two hours of the conclusion of the call, by dialing [phone] from the U.S., or [phone] for international callers, and entering reservation number 4706336. Individuals interested in listening to the conference call via the Internet may do so by visiting www.tercica.com. A replay will be available on the Company's Web site for 21 days.

About Tercica and Increlex

Tercica, Inc. is a biopharmaceutical company focused on the development and commercialization of products to improve endocrine health. The company's first product, Increlex (mecasermin (rDNA origin) injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. For further information on Tercica, please visit www.tercica.com.

Insulin-like Growth Factor-1 (IGF-1) is the principal hormone necessary for statural growth, and is released in response to stimulation by growth hormone. Primary IGFD is diagnosed in children who have normal or elevated secretion of endogenous growth hormone yet are resistant to its effects, and whose height and serum IGF-1 levels are more than two standard deviations below normal. A sub-set of these children, whose height and serum IGF-1 levels are more than three standard deviations below normal, are diagnosed with severe Primary IGFD.

Safe Harbor statement

Except for the historical statements contained herein, this press release contains forward-looking statements, including without limitation the statements that the Company: (1) estimates that the severe Primary IGFD population in the EU is approximately equal to that in the U.S.; and (2) expects that cash burn in 2006, including working capital requirements and excluding the impact of revenue and related product costs, is expected to be in the range of $63 million to $69 million. Because Tercica's forward-looking statements are subject to risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include without limitation those risks and uncertainties disclosed from time to time in periodic reports filed by Tercica with the SEC, in Tercica's Form 424(B5) filed on January 24, 2006; and with respect to (1) above, there may be fewer children than Tercica estimates; and with respect to (2) above, the Company may spend more for clinical trials, new development projects, litigation, or for other reasons. These statements are based on information as of February 15, 2006, and the Company assumes no obligation to update any forward-looking statement.

TERCICA, INC.
(A DEVELOPMENT-STAGE COMPANY)

(In thousands, except per share data)
(Unaudited)

Three Months Ended Year Ended
Statements of Operations December 31, December 31,
------------------- -------------------
2005 2004 2005 2004
--------- --------- --------- ---------
Costs and expenses:
Research and development(a) $4,716 $7,646 $21,587 $27,918
Selling, general and
administrative(a) 8,882 3,795 25,913 12,552
Acquired in-process
research and development -- -- -- 1,417
--------- --------- --------- ---------
Total costs and expenses (13,598) (11,441) (47,500) (41,887)
Interest expense (181) -- (1,080) --
Interest income 651 252 2,427 885
Other expense, net (1,274) -- (1,276) --
--------- --------- --------- ---------
Net loss $(14,402) $(11,189) $(47,429) $(41,002)
========= ========= ========= =========


Basic and diluted net loss per
share $(0.46) $(0.46) $(1.55) $(2.12)
========= ========= ========= =========
Shares used to compute basic
and diluted net loss per share 31,534 24,064 30,590 19,302
========= ========= ========= =========


-------------------------------
(a) Includes non-cash
stock-based compensation
expense as follows:
Research and development $253 $291 $1,188 $1,386
Selling, general and
Administrative 198 379 1,006 1,455
--------- --------- --------- ---------
Total $451 $670 $2,194 $2,841
========= ========= ========= =========


December 31, December 31,
2005 2004
------------ ------------
(1)
Balance Sheet Data

Cash, cash equivalents and
short-term investments $58,626 $52,001
Total assets 66,316 55,022
Total liabilities 9,518 7,345
Total stockholders' equity 56,798 47,677

(1) Derived from the audited financial statements for the year ended
December 31, 2004 included in the Company's Form 10-K.

SOURCE: Tercica, Inc.

Tercica, Inc.
Investors:
Ina McGuinness, 650-624-4949
[e-mail]
or
Media:
Kathleen Rinehart, 650-624-4948
[e-mail]

[coinstarz]

TRCA: New 52-Wk Low @ $6.250 dn 5.16%

Friday , February 10, 2006 09:55 ET

This is the 1st 52 WEEK LOW alert for TRCA in the past 7 calendar days.

The share price for Tercica,Inc. (NASDAQ NM: TRCA) reached a new 52-week low today, trading at $6.250, down $-0.340 (-5.16%) from its previous close of $6.590.

The Company's previous 52-week low of $6.300 was set 15 days ago on January 26, 2006.

One year ago, the Company's shares closed at $8.350. The price has declined more than 25 percent since then.

At the time of this alert, the stock had traded 47,800 shares via 39 trades, 74.36% below it's 20day average of 186,400 shares.

This new 52-week low currently puts the stock:

7.96% below its 20day Moving Average of $6.790
17.32% below its 50day Moving Average of $7.560
29.57% below its 100day Moving Average of $8.875

The Company last released news on February 01, 2006:

"Tercica to Hold 2005 Fourth Quarter and Year End Financial Results Conference Call February 15"

[coinstarz]

Tercica Announces $30 Million Financing
Business Wire - January 24, 2006 09:47

BRISBANE, Calif., Jan 24, 2006 (BUSINESS WIRE) -- Tercica, Inc. (NASDAQ:TRCA) announced today that it is selling 5,000,000 shares of its common stock pursuant to an effective shelf registration statement. Tercica expects the net proceeds from the sale of the shares to be approximately $30 million, after deducting underwriting discounts and commissions, but before the expenses of the offering. Tercica also granted to the underwriter a 30-day option to purchase up to an additional 750,000 shares of common stock. All of the shares in the offering are being sold by Tercica. Lehman Brothers Inc. is acting as sole underwriter for the offering. Tercica expects the closing of the offering to occur on or about January 27, 2006.

A registration statement relating to these securities has been filed with and declared effective by the Securities and Exchange Commission. Additional information and details with respect to the offering will be included in a final prospectus supplement and related prospectus that will be filed with the Securities and Exchange Commission prior to closing. When available, the final prospectus supplement and the related prospectus may be obtained from Lehman Brothers Inc., c/o ADP Financial Services, Integrated Distribution Services, 1155 Long Island Avenue, Edgewood, NY 11717, 631-254-7106.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities, nor shall there be any sale of these securities, in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Tercica

Tercica, Inc. is a biopharmaceutical company focused on the development and commercialization of products to improve endocrine health. Tercica's first product, Increlex(TM), or recombinant human insulin-like growth factor-1 (rhIGF-1) is approved by the FDA for the long-term treatment growth failure due to severe Primary IGFD. For further information on Tercica, please visit www.tercica.com.

Safe Harbor Statement

This press release contains "forward-looking statements." For this purpose, any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements, including, without limitation, statements regarding Tercica's plans to complete a public offering. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Tercica's results to differ materially from those indicated by these forward-looking statements, including without limitation, risks and uncertainties related to satisfaction of customary closing conditions related to the public offering. There can be no assurance that Tercica will complete the offering of the common stock on the anticipated terms, or at all. In addition, Tercica's business is subject to the risks detailed in Tercica's filings with the Securities and Exchange Commission, including the preliminary prospectus supplement and related prospectus with respect to the offering filed on January 24, 2006. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Tercica undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

SOURCE: Tercica, Inc.

[coinstarz]

Good News for TRCA investors.

http://biz.yahoo.com/bw/060103/20060103005288.html?.v=1

To be fair, I wish TRCA investors best in 2006.

[cosmoworld7]

who wrote that silly letter?

[coinstarz]

Dear TRCA VP - a letter.
by: wimalwayswin
Long-Term Sentiment: Hold 12/17/05 09:29 am
Msg: 1404 of 1415

I can understand your concern today. It would keep me awake too in such a situation.

I can however not understand your reaction. I believe you are making a wrong judgement.

Adding to the negative, by lawsuit and legal claiming is not helping anybody but the lawyers.

I believe that you trapped yourself when you entered the lawsuit. Its a loose/loose situation in my opinion.

Medicins are here for the people and it is them who will compare your treatments, not the court of law. Fight your battles on the marketplace.

As an MD you should practice science from the point of helping people. Am sure you remember Hipocrates.

If a competitive drug or science enters the market you should not start a fight on the benefits that it may give the people.
That just shows them you are more interested in your pockets than in making a scientific or healthcaring difference.

There are other ways.

With the money you will pay your lawyers NOBODY with IGF-1 seems helped to me.
What a shame. I thought helping them was the whole purpose.

Merry Christmas,
This is just my opinion and I wish you good luck.

http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=1608000820&tid=trca&sid=...